Investment Rating - The report maintains an "OUTPERFORM" rating for Jinxin Fertility [1][2]. Core Views - The demand for assisted reproductive technology (ART) in China is expected to reach a turning point, driven by delayed childbearing and the gradual release of policy benefits. The average childbearing age in China is approaching 30, leading to an increase in the proportion of older mothers and a significant rise in demand for ART [3][29]. - The company's overseas business is experiencing strong growth, particularly in the U.S., where the number of egg retrieval cycles is projected to increase by 18.2% year-on-year in 2024. New policies in California are expected to further boost demand for ART services [3][4]. Summary by Sections 1. Future Trends in China's Assisted Reproductive Demand - The number of newborns in China is expected to stabilize in 2024, with a continuous increase in the proportion of births from older mothers. The average childbearing age has risen to 29.0 years, with a significant demand for ART from older women [14][16]. - The penetration rate of ART in China is anticipated to accelerate as the average childbearing age surpasses 30, similar to trends observed in other developed countries [19][20]. - Payment policies are identified as a core factor influencing ART penetration rates, with significant room for improvement in China's healthcare insurance and subsidy policies [25][26]. 2. Revenue and Profit Outlook for Domestic and Overseas Businesses - The company's revenue for 2024 is projected at RMB 28.1 billion, reflecting a modest growth of 0.8%, primarily due to patients delaying treatment in anticipation of policy changes [34]. - The domestic business is expected to stabilize, while the overseas business, particularly in the U.S., is set to grow significantly due to an increase in the number of doctors and favorable policy changes [38][40]. - The company has successfully controlled costs, with a sales and management expense ratio of approximately 22.5%, which has helped mitigate pressure on profit margins [44]. 3. Profit Forecast and Valuation - The company is expected to achieve revenues of RMB 29.9 billion and RMB 32.6 billion in 2025 and 2026, respectively, with growth rates of 6.4% and 9.0% [5][46]. - The adjusted net profit is forecasted to be RMB 4.2 billion and RMB 4.7 billion for the same years, with growth rates of 0.9% and 10.5% [5][46]. - The target price for the company's stock is set at HKD 3.69, corresponding to a price-to-earnings ratio of 22x for 2025 and 20x for 2026, reflecting confidence in the company's long-term value as a leader in the assisted reproductive sector [49].
锦欣生殖（01951）：更新报告：晚育、中美政策红利有望改善需求和支付端